Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate prophylaxis after human leukocyte antigen (HLA)-mismatched reduced intensity conditioning allogeneic hematopoietic stem cell transplantation documented low acute graft-versus-host disease incidence, with promising overall and progression-...

Descripción completa

Detalles Bibliográficos
Autores principales: Koreth, John, Kim, Haesook T., Lange, Paulina B., Poryanda, Samuel J., Reynolds, Carol G., Rai, Sharmila Chamling, Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Glotzbecker, Brett, Yusuf, Rushdia, Nikiforow, Sarah, Chen, Yi-Bin, Dey, Bimalangshu, McMasters, Malgorzata, Ritz, Jerome, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Alyea, Edwin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830392/
https://www.ncbi.nlm.nih.gov/pubmed/29326124
http://dx.doi.org/10.3324/haematol.2017.176859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830392/
https://www.ncbi.nlm.nih.gov/pubmed/29326124
http://dx.doi.org/10.3324/haematol.2017.176859

Ejemplares similares